Abstract
Cariprazine, an orally active and potent dopamine D3–preferring D3/D2 receptor partial agonist, is approved to treat adults with schizophrenia (in the United States and Europe) and manic or mixed episodes associated with bipolar I disorder (in the United States). Cariprazine also displays partial agonism at serotonin [5-hydroxytryptamine (5-HT)] 5-HT1A receptors and antagonism at 5-HT2A and 5-HT2B receptors in vitro. The study objective was to determine whether cariprazine leads to functional alterations of monoamine systems in vivo via electrophysiological recordings from anesthetized rats. Dorsal raphe nucleus (DRN), locus coeruleus (LC), and hippocampus pyramidal neurons were recorded, and cariprazine was administered systemically or locally through iontophoresis. In the DRN, cariprazine completely inhibited the firing activity of 5-HT neurons, which was fully reversed by the 5-HT1A receptor antagonist, WAY100635. In the LC, cariprazine reversed the inhibitory effect of the preferential 5-HT2A receptor agonist, 2,5-dimethoxy-4-iodoamphetamine, on norepinephrine (NE) neurons (ED50 = 66 µg/kg) but did not block the inhibitory effect of the α2-adrenergic receptor agonist, clonidine. Cariprazine, iontophorized into the hippocampus, diminished pyramidal neuronal firing through activation of 5-HT1A receptors, while its concomitant administration did not dampen the suppressant effect of 5-HT. These results indicate that, in vivo, cariprazine acted as a 5-HT1A autoreceptor agonist in the DRN, a 5-HT2A receptor antagonist in modulating the firing activity of LC NE neurons, and a full agonist at 5-HT1A receptors mediating the electrophysiological effect of 5-HT on pyramidal neurons. The modulatory actions of cariprazine on these monoaminergic systems may contribute to its therapeutic effectiveness in patients with depressive episodes.
Introduction
Cariprazine (in the United States: Vraylar; in Europe: Reagila) is a novel dopamine (DA) D3–preferring D3/D2 receptor and serotonin [5-hydroxytryptamine (5-HT)] 5-HT1A receptor partial agonist that has been approved to treat schizophrenia (in the United States and Europe) and manic or mixed episodes associated with bipolar I disorder (in the United States). It was recently reported that adjunctive cariprazine was efficacious in patients who had an inadequate response to their medications used to treat major depressive disorder (Durgam et al., 2016a). Cariprazine has also shown efficacy in improving symptoms of depressive episodes in patients with bipolar I disorder (Durgam et al., 2016b). Unlike aripiprazole, another DA receptor partial agonist indicated for the treatment of schizophrenia and bipolar disorder, cariprazine acts as a D3/D2 receptor partial agonist with higher binding affinity and selectivity (5- to 8-fold) for D3 versus D2 receptors and as a more potent antagonist at 5-HT2A receptors in vitro (Lawler et al., 1999; Kiss et al., 2010; Maeda et al., 2014). In addition to these properties, cariprazine was shown in vitro to be a partial agonist at 5-HT1A receptors in hippocampal tissue, a high-affinity antagonist at 5-HT2B receptors, and to have moderate affinity for histamine type 1 receptors (Kiss et al., 2010).
The role of 5-HT1A receptors in depression has been demonstrated by findings that the 5-HT1A receptor agonists buspirone and gepirone are effective antidepressants, either as a monotherapy or in combination with selective serotonin reuptake inhibitors (SSRIs) for acute treatment and relapse prevention (Trivedi et al., 2006; Bielski et al., 2008; Fabre et al., 2011). In addition, activation of 5-HT1A receptors by selective agonists such as 8-OH-DPAT increases DA release in the prefrontal cortex (Arborelius et al., 1993; Li et al., 2004; Assié et al., 2005).
Several lines of evidence suggest that blockade of 5-HT2A receptors in combination with SSRI treatment may contribute to substantial therapeutic benefits in major depressive disorder (Blier and Szabo, 2005). Indeed, medications that block 5-HT2A receptors, such as aripiprazole, quetiapine, risperidone, and olanzapine, as well as mirtazapine and mianserin, are effective augmentation strategies in combination with SSRIs (Nelson and Papakostas, 2009; Kennedy et al., 2016). The only property that the aforementioned drugs have in common is their capacity to block 5-HT2A receptors. Thus, it is likely that the 5-HT2A receptor antagonistic property of these agents acts by removing the inhibitory effects of SSRIs on norepinephrine (NE) systems (Szabo and Blier, 2002; Seager et al., 2004; Dremencov et al., 2007; Chernoloz et al., 2009, 2012).
In vitro studies are necessary to identify potential therapeutic compounds, but it is also important to study the activity of a drug in vivo to have a thorough mechanistic understanding. Prior experiments of this nature have been conducted to characterize the effects of cariprazine on DA neurons (Delcourte et al., 2018) but not on 5-HT or NE systems. To this end, the objectives of the present study were to determine the in vivo effects of acute cariprazine administration at 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN), postsynaptic 5-HT1A receptors in the hippocampus, 5-HT2A receptors controlling NE neuron firing in the locus coeruleus (LC), and α2-adrenergic autoreceptors within the LC using electrophysiological techniques.
Materials and Methods
Animals.
The experiments were carried out on male Sprague-Dawley rats (Charles River Laboratories, St. Constant, QC, Canada) weighing 250–350 g and housed in groups of two per cage, under standard laboratory conditions (12-hour light/dark cycle with food and water ad libitum). In vivo extracellular recordings were carried out in chloral hydrate–anesthetized rats (400 mg/kg, intraperitoneal [i.p.]) that were mounted in a stereotaxic apparatus. Supplemental doses of the anesthetic (100 mg/kg, i.p.) were given to maintain constant anesthesia and prevent nociceptive reaction to pinching of the hind paws. Body temperature was maintained at 37°C throughout the experiment via a thermistor-controlled heating pad. Prior to electrophysiological recordings, a catheter was inserted in a lateral tail vein for systemic intravenous injection of pharmacologic agents. Recordings were generally carried out within 30–60 minutes after achieving complete anesthesia. All experiments were carried out in accordance with the Canadian Council on Animal Care and the local Animal Care Committee (Royal Ottawa Institute of Mental Health Research, Ottawa, Canada).
Compounds.
The preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI), the α2-adrenergic agonist clonidine, and the selective 5-HT1A receptor antagonist WAY100635 were dissolved in distilled water. Cariprazine [see the chemical structure given in Kiss et al. (2010)] was dissolved in 5% lactic acid and distilled water for intravenous (i.v.) injection. Cariprazine was provided by Allergan (Dublin, Ireland); all other compounds were purchased from Tocris Bioscience (Minneapolis, MN).
In Vivo Electrophysiological Recordings.
A burr hole was drilled at the stereotaxic coordinates corresponding to the brain structure of interest (Paxinos and Watson, 2007). Extracellular recordings of neurons in the DRN and LC were carried out using single-barrel glass micropipettes (Stoelting, Spencerville, MD) preloaded with 2 M NaCl and with impedance between 2 and 6 MΩ. Neurons in the cornu ammonis 3 (CA3) region of the hippocampus were recorded with five-barrel micropipettes. The central barrel (used for unitary recordings) and one side barrel (used for automatic current balancing) were filled with 2 M NaCl; the other barrels were filled with cariprazine (10 mM in distilled water and 5% lactic acid, pH 4), 5-HT creatinine sulfate (15 mM in 0.2 M NaCl, pH 4), or quisqualic acid (1.5 mM in 0.2 M NaCl, pH 8). Cariprazine and 5-HT were ejected as cations and retained with a negative current; quisqualate was ejected as an anion and retained with a positive current. Drugs injected intravenously were administered in 0.1 ml aliquots at 60-second intervals to ensure stabilization of the recording and to determine drug effects in incremental doses; these recordings lasted 20 minutes on average.
Recording of DRN 5-HT Neurons.
Putative 5-HT neurons were recorded by positioning single-barrel glass micropipettes at the following coordinates (in millimeters from lambda): anterior/posterior, 1.0–1.2; mediolateral, 0; and dorsal/ventral, 5.0–7.0. The following criteria were used to identify 5-HT neurons: a bi- or triphasic extracellular wave form with long-duration (0.8–1.2 milliseconds), positive phase, and regular firing in the range of 0.5–2.5 Hz were recorded (Vandermaelen and Aghajanian, 1983).
Systemic intravenous injections were used to obtain the net effect of cariprazine on the firing of 5-HT neurons since it is one of the main factors controlling 5-HT transmission. Subsequent injection of the selective 5-HT1A receptor antagonist WAY100635 served to determine the 5-HT1A nature of the suppression of firing. Full and partial 5-HT1A receptor agonists should suppress all 5-HT firing and lead to restoration of firing after prolonged administration through desensitization of the 5-HT1A autoreceptor (Blier and El Mansari, 2013); therefore, the intrinsic activity of cariprazine at the 5-HT1A autoreceptor was not determined as for the hippocampus.
Recording of LC NE Neurons.
The NE neurons were recorded by positioning single-barrel glass micropipettes at the following coordinates (in millimeters from lambda): anterior/posterior, −1.1 to −1.2; mediolateral, 1.0–1.3; and dorsal/ventral, 5.0–7.0. The following criteria were used to identify NE neurons: regular firing rate (1.0–5.0 Hz), long duration (0.8–1.2 milliseconds) of the action potential, and brisk excitatory response followed by a short period of inhibition in reaction to a nociceptive pinch of the contralateral hind paw (Aghajanian et al., 1977). To test the effect of cariprazine on 5-HT2A receptors, NE neurons were suppressed by the preferential 5-HT2A receptor agonist DOI (Szabo and Blier, 2001). Following an inhibition period, cumulative intravenous doses of cariprazine were administered to antagonize the inhibitory effect of DOI. The reversing effect of cariprazine was quantified relative to the stable baseline firing activity for over at least a 60-second interval preceding the intravenous injection.
Systemic intravenous injections of various drugs were used to obtain their net effect on the firing rate of NE neurons, since it is one of the main determinants of NE transmission. DOI had to be injected intravenously and not locally applied, because the 5-HT2A receptors controlling the NE neuron firing activity are not located in the LC (Szabo and Blier, 2001).
Recording of Pyramidal Neurons in the CA3 Region of the Hippocampus.
The CA3 pyramidal neurons were recorded by positioning multibarrel micropipettes at the following coordinates (in millimeters from lambda): anterior/posterior, 3.8–4.2; mediolateral, 4.0–4.2; and dorsal/ventral, 3.5–4.5. Because most CA3 pyramidal neurons are not spontaneously active in chloral hydrate-anesthetized rats, a small ejection current (+2 to −2 nA) was applied to the quisqualate barrel to activate them to be within their physiologic firing range (10–15 Hz) (Ranck, 1975). Partial or full agonism of cariprazine on 5-HT1A receptors cannot be assessed in vivo using systemic injections. Therefore, it was assessed by comparing the inhibitory effect of 5-HT, per se, to the inhibitory effect of concomitant ejection of 5-HT and cariprazine, following restoration of the firing rate to the same level as before by increasing quisqualate ejection. In this paradigm, coapplication of a partial agonist reduces the inhibitory effect of 5-HT, whereas coapplication of a full agonist does not change the inhibitory effect of 5-HT, provided the ensuing concentration of the agent tested against 5-HT (cariprazine here) is initially sufficient to induce inhibition of the firing activity of pyramidal neurons by at least 50% (Blier and de Montigny, 1990; Dong et al., 1998; Ghanbari et al., 2009, 2010; Oosterhof et al., 2014). To ascertain whether the inhibitory effect of 5-HT and cariprazine was mediated by 5-HT1A receptors, the inhibitory effect of iontophoretic 5-HT and cariprazine application was compared before and after administration of the selective 5-HT1A receptor antagonist WAY100635.
Data Analysis.
Electrophysiological recordings were made using Spike2 software version 6.17 (Cambridge Electronic Design, Cambridge, UK). Quantification of firing rates was performed using Spike2. When appropriate, groups were analyzed with a paired t test or with repeated-measures analysis of variance followed by a Holm-Sidak method. All data were analyzed with GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA). Data are presented as mean ± S.E.M.; P < 0.05 was considered significant.
Results
Effect of Cariprazine on the Firing Activity of DRN 5-HT Neurons.
The role of cariprazine in inhibiting the firing activity of 5-HT neurons via 5-HT1A autoreceptors was investigated in the DRN. Cumulative intravenous injections of 50 µg/kg of cariprazine decreased the firing activity of 5-HT neurons (n = 15 rats; one neuron per animal). This effect was subsequently reversed by the selective 5-HT1A receptor antagonist WAY100635, indicating that cariprazine was acting as an agonist at the 5-HT1A autoreceptors in vivo (Fig. 1A).
(A) Integrated firing rate histogram of a single 5-HT neuron showing its response to four cumulative intravenous injections of cariprazine and the subsequent reversal with an intravenous dose of the selective 5-HT1A antagonist WAY100635. (B) Relationship between the number of 5-HT neurons showing 100% inhibition of firing and the dose of cariprazine necessary to achieve the complete suppression of firing. One neuron was recorded per rat. (C) No significant correlation between the degree of firing activity of 5-HT neurons and the dose of cariprazine necessary to achieve complete inhibition.
Although the response was dose dependent for each neuron tested, the degree of firing inhibition for a given dose varied considerably. Indeed, the dose required to completely inhibit the firing rate ranged from a minimum of 150 µg/kg to a maximum of 850 µg/kg (Fig. 1B). However, 80% of the tested neurons (n = 12 of 15) were completely inhibited by cumulative intravenous doses of cariprazine within a range of 150–350 µg/kg. Upon detailed analysis, there was no correlation between the initial baseline firing rate of an individual 5-HT neuron and the cariprazine dose required to completely inhibit the firing (Fig. 1C).
Effect of Cariprazine on Postsynaptic 5-HT1A Receptors on Pyramidal Neurons in the Hippocampus.
Microiontophoretic application of cariprazine significantly inhibited the firing activity of pyramidal neurons, as did 5-HT (Fig. 2A). There was no statistically significant difference between the degree of inhibition induced by 5-HT alone compared to when it was concomitantly applied with cariprazine (P > 0.05; Fig. 2, A and B), indicating that cariprazine acted as a full agonist at 5-HT1A receptors in vivo in the hippocampus.
(A) Integrated firing rate histogram of a single pyramidal neuron in the hippocampus, showing inhibition by cariprazine and 5-HT. Note that one-way analysis of variance with repeated measures showed subsequent full inhibition by 5-HT was not significantly different when concomitantly administered with cariprazine (A and B). (C and D) Both inhibitions induced by cariprazine and 5-HT were antagonized by the intravenous injection of the selective 5-HT1A receptor antagonist WAY100635. The number of neurons and animals are presented in the histograms; data were analyzed with a paired t test and are presented as mean ± S.E.M. **P < 0.01; ***P < 0.001 for effect of WAY100635 administration on the inhibitory effect of cariprazine and 5-HT.
The effects of ejecting cariprazine and 5-HT in the CA3 pyramidal neurons were assessed after an intravenous injection of the selective 5-HT1A receptor antagonist WAY100635 (50 μg/kg) to confirm that these two substances were acting through the 5-HT1A receptor. Indeed, the degree of inhibition induced by both cariprazine and 5-HT was significantly reduced by the antagonist (**P < 0.01, ***P < 0.001, respectively; Fig. 2, C and D).
Effect of Cariprazine on the Firing Activity of LC NE Neurons: Role of 5-HT2A Receptors and α2-Adrenergic Receptors.
The preferential 5-HT2A receptor agonist DOI (100 µg/kg, i.v.) induced near complete cessation of NE neuronal firing (Fig. 3A). Cumulative intravenous injections of 50 µg/kg of cariprazine restored the firing activity up to 70% of the baseline level, with an ED50 value of 65.5 µg/kg (Fig. 3; n = 7).
(A) Integrated firing rate histogram showing DOI-induced inhibition of NE neuronal firing by the preferential 5-HT2A receptor agonist DOI and its reversal by cumulative doses of cariprazine. Note subsequent inhibition by clonidine and reversal by idazoxan. (B) Dose-response curve showing the percentage reversal of DOI-induced inhibition relative to baseline in NE neurons by cumulative doses of cariprazine (n = 7, one neuron was recorded per rat).
As shown in Fig. 4, in the presence of cariprazine, the effect of the α2-adrenoceptor agonist clonidine was compared with its effect under control conditions. After cariprazine pretreatment, clonidine fully inhibited the firing activity of NE neurons upon dosing with two cumulative injections (10 µg/kg, i.v.) as it did in control conditions (Fig. 4). The effects of clonidine on NE neuronal firing were reversed by administration of the α2-adrenoceptor antagonist idazoxan (1 mg/kg, i.v.), indicating that cariprazine did not block α2-adrenoceptors (Fig. 4).
Representative integrated firing rate histograms illustrating inhibition of NE neuron firing activity by clonidine (A), and the lack of effect of cariprazine on this activity following pretreatment with cariprazine (B and C). Note that this inhibition is reversed by the intravenous injection of the α2-adrenoceptor idazoxan.
Discussion
In the DRN, cariprazine fully inhibited the firing activity of 5-HT neurons. This effect was reversed by the selective 5-HT1A receptor antagonist WAY100635, which indicated that cariprazine acted as an agonist in vivo at the 5-HT1A autoreceptors in this brain structure. Although cumulative doses inducing inhibition varied for each 5-HT neuron tested, the effect of cariprazine was dose dependent for each neuron; nevertheless, the majority of neurons were inhibited by doses ranging between 150 and 350 µg/kg. A potential role of α1-adrenoceptors in altering the responsiveness of 5-HT neurons to cariprazine, as is the case with olanzapine and clozapine (Sprouse et al., 1999), can be excluded since cariprazine has very weak or negligible affinity for these receptors (Kiss et al., 2010). It could be assumed that the varied neuronal responsiveness of 5-HT1A autoreceptors to cariprazine stems from differences in baseline firing of individual neurons, since a previous study suggested that 5-HT neurons with slow firing activity are more sensitive to 5-HT receptor agonists than neurons with faster discharge (Jacobs et al., 1983). In the present study, however, this variable response was not related to the baseline firing rate of individual neurons. Such variation in the degree of inhibition was unexpected because all selective 5-HT1A receptor agonists and other agents with 5-HT1A receptor partial agonist activity (e.g., aripiprazole and brexpiprazole) tested in this paradigm yielded a tight dose-response relationship upon systemic administration, unlike cariprazine (Blier and de Montigny, 1990; Dong et al., 1998; Rueter and Blier, 1999; Dahan et al., 2009; Oosterhof et al., 2014). Interestingly, both aripiprazole and brexpiprazole display greater in vitro affinity for 5-HT1A receptors than cariprazine but were less potent than cariprazine in activating the 5-HT1A autoreceptors (Dahan et al., 2009; Oosterhof et al., 2014; Citrome, 2015). Therefore, a potential explanation for the wide range of cariprazine doses needed to inhibit 5-HT neurons may be due to the balance of the inhibitory effect of 5-HT1A receptor activation versus the excitatory action of D2-like receptors for different 5-HT neurons (Chernoloz et al., 2009). Indeed, 5-HT neurons are endowed with D2-like receptors that mediate an excitatory influence on neuronal firing (Aman et al., 2007; Katz et al., 2010). This explanation can be envisioned if it is assumed that the 5- to 8-fold greater binding affinity and selectivity of cariprazine for D3 versus D2 receptors, compared with aripiprazole and brexpiprazole (which show a lower affinity for D3 receptors and a higher selectivity for D2 vs. D3 receptors than cariprazine), exert a larger excitatory effect on some 5-HT neurons. Interestingly, D3 receptor expression has been demonstrated by binding assays in the median and dorsal raphe nuclei of the midbrain (Stanwood et al., 2000), and thus may also influence 5-HT neuronal firing in this region. However, further studies using selective tools are needed to explore the specific role of the D3 receptor on 5-HT neuronal activity. At this point, it is unclear whether the variability in the response of 5-HT neurons to cariprazine translates into a functional difference compared, for example, to other DA receptor partial agonists such as brexpiprazole and aripiprazole. Nevertheless, although cariprazine and aripiprazole had a superior effect on mood symptoms when compared with placebo, the magnitude of their effect appears to be similar in patients with schizophrenia (Durgam et al., 2015).
In the hippocampus, cariprazine did not reduce the effectiveness of the endogenous ligand 5-HT at postsynaptic 5-HT1A receptors when the two compounds were applied concomitantly. This indicates that cariprazine acted as a full 5-HT1A receptor agonist in this brain region. Similar to cariprazine, brexpiprazole has also been shown to act as a full agonist at the postsynaptic 5-HT1A receptors in the hippocampus (Oosterhof et al., 2014). It is also important to note that agents acting on 5-HT1A receptors can have heterogeneous effects at 5-HT1A receptors in different brain areas. For instance, studies of the 5-HT1A receptor agonist/5-HT2A receptor antagonist flibanserin revealed that it acts as a full agonist at presynaptic 5-HT1A receptors in the DRN and at postsynaptic 5-HT1A receptors in the medial prefrontal cortex, but as a partial agonist at the postsynaptic 5-HT1A receptors in the CA3 region of the hippocampus (Reuter and Blier, 1999). Moreover, it was reported that selective activation of these postsynaptic receptors enhances 5-HT transmission and DA release in the medial prefrontal cortex (Chung et al., 2004). Indeed, activation of 5-HT1A receptors (by 5-HT1A receptor agonists) was shown to increase DA release in the medial prefrontal cortex (Ichikawa et al., 2001; Díaz-Mataix et al., 2005).
A previous study has shown that both aripiprazole and cariprazine decreased 5-HT turnover rate in mouse prefrontal cortex through an action on 5-HT1A receptors (Kiss et al., 2010). In various in vitro assays, cariprazine was shown to act either as a partial agonist (Kiss et al., 2010) or full agonist depending on the assay system used. The present in vivo study found that cariprazine acted rather as a full agonist at 5-HT1A receptors controlling the firing activity of pyramidal neurons in the hippocampus. It has been suggested that a partial agonist can behave differently depending on the level of receptor reserve; for example, the partial agonist may behave as expected or even as an antagonist in tissue with low or negligible levels of receptor reserve, but in the presence of high levels of receptor reserve that same partial agonist may behave like a full agonist instead (Kenakin, 1987). This is, however, not the case with the in vivo electrophysiological response reported herein because, with the approach used in this study, both partial and full 5-HT1A receptor agonists have been identified in the DRN and hippocampus (Blier and de Montigny 1990; Dong et al., 1998; Ghanbari et al., 2009, 2010; Oosterhof et al., 2014). It is nevertheless possible that these responses are partially dependent on the coupling between specific 5-HT1A receptors and the signal transduction mediating their response (Valdizán et al., 2010). Indeed, in the hippocampus 5-HT1A receptors are coupled to adenylyl cyclase but also to potassium channels, the latter being involved in the electrophysiological responses measured in this study, and both of which have displayed differential properties in previous studies (Yocca et al., 1992; Blier et al., 1993).
Cariprazine acted as a potent antagonist at 5-HT2A receptors on LC NE neurons, since it reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI. These receptors are located on GABA neurons that control the activity of NE neurons (Haddjeri et al., 1997; Szabo and Blier, 2002). Interestingly, administration of YM992 (a 5-HT2A receptor antagonist and an inhibitor of 5-HT reuptake) or blockade of 5-HT2A receptors by the selective 5-HT2A receptor antagonist MDL100907 during treatment with the SSRI citalopram was shown to synergistically increase cortical NE levels, which were measured by microdialysis (Hatanaka et al., 2000). Furthermore, blockade of 5-HT2A receptors by various medications, such as risperidone, aripiprazole, and olanzapine, reverses the inhibitory effect of SSRIs on LC NE neurons (Seager et al., 2004; Dremencov et al., 2007; Chernoloz et al., 2009). Despite the lower in vitro binding affinity of cariprazine for 5-HT2A receptors when compared with other drugs commonly used to treat psychosis and mania (Ghanbari et al., 2009; Oosterhof et al., 2014), its in vivo 5-HT2A receptor antagonist potency for reversing the inhibitory effect of DOI was similar to those medications.
The α2-adrenergic autoreceptors were not blocked by cariprazine in the present study. Indeed, cariprazine pretreatment did not result in dampening of the inhibitory action of the α2-adrenoceptor agonist clonidine on NE neurons; this is consistent with its weak or negligible affinity for these receptors as determined by in vitro binding assays (Kiss et al., 2010). It is interesting to note that this lack of effect on α2-adrenergic receptors differs from other medications used to treat psychosis and/or mania (Dremencov et al., 2007; Ghanbari et al., 2009; Oosterhof et al., 2014).
It is important to consider whether the doses of cariprazine used in the present experiments produced plasma levels within the range of those achieved in humans. Because 5-HT2A antagonism is an important feature of this class of medication, both in mood disorders and schizophrenia, the cariprazine concentrations that reversed the effect of the 5-HT2A receptor agonist DOI by cariprazine in the LC were used for comparison with human plasma concentrations. Given that a dose of 1 mg/kg of cariprazine (intravenous) results in a peak plasma level of 240 ng/ml in rats (Gyertyán et al., 2011), it can be extrapolated that the 0.2 mg/kg dose of cariprazine necessary to reverse the suppression of firing by DOI should have produced a level of 48 ng/ml in plasma. This is consistent with the 50 ng/ml plasma level of cariprazine active moieties reported in patients receiving cariprazine at 3 mg/d (Nakamura et al., 2016).
In this study, in agreement with its in vitro affinity, cariprazine showed acute in vivo activity with effective agonism at 5-HT1A receptors and antagonism at 5-HT2A receptors. Agonism at 5-HT1A receptors has been shown to play a key role in the control of mood and cognition (Newman-Tancredi, 2010), while antagonism at 5-HT2A receptors is thought to play a role in modulating the NE system. Hence, it is possible that the activation of 5-HT1A receptors and the blockade of 5-HT2A receptors by cariprazine may contribute to its beneficial therapeutic action seen in major depressive disorder (Durgam et al., 2016a) and bipolar depression (Durgam et al., 2016b).
Acknowledgments
Editorial support for manuscript preparation was provided by Katharine Fang of Prescott Medical Communications Group, Chicago, IL (a contractor of Allergan).
Authorship Contributions
Participated in research design: El Mansari, Kiss, Farkas, Blier.
Conducted experiments: Herman, El Mansari.
Wrote or contributed to the writing of the manuscript: Herman, El Mansari, Adham, Kiss, Farkas, Blier.
Footnotes
- Received June 6, 2018.
- Accepted October 4, 2018.
This work was financially supported by Allergan (Madison, NJ) and Gedeon Richter Plc (Budapest, Hungary).
Abbreviations
- 5-HT
- 5-hydroxytryptamine (serotonin)
- CA3
- cornu ammonis 3
- DA
- dopamine
- DOI
- 2,5-dimethoxy-4-iodoamphetamine
- DRN
- dorsal raphe nucleus
- LC
- locus coeruleus
- NE
- norepinephrine
- SSRI
- selective serotonin reuptake inhibitor
- Copyright © 2018 The Author(s).
This is an open access article distributed under the CC BY Attribution 4.0 International license.
